

**NANETS 2023 Multidisciplinary NET Medical  
Symposium  
Montreal, Quebec  
October 4-6, 2023**

**Continuing Education Information**

This continuing education activity is provided through collaboration between the North American Neuroendocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, nurses, pharmacists, and technologists. A statement of participation is available for other attendees.

**Learning Objectives**

- Examine the role of Medical Oncologists in NET care in the community
- Evaluate models for pharmacist collaboration with providers in caring for patients with cancer
- Review the resources needed to provide optimal NET care in the community
- Describe commonly used liver-directed therapies, appropriate utilization, and mechanisms of action
- Review the application of liver-directed therapy in a personalized manner based on tumor genetics and biomarkers
- Define strategies that could help decrease disparities in access to subspecialty neuro-endocrine care
- Recognize limitations and pitfalls of radiographic evaluation
- Describe how radiation therapy may be optimally incorporated with the increasing use of immunotherapy for Merkel Cell Carcinoma
- Review updates in the management of carcinoid heart disease (CHD)
- Recognize the importance of multidisciplinary discussion in oligometastatic disease related to surgery or radiotherapy in NET

**Disclosures**

AffinityCE staff, NANETS staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below, available on the program website, and will be stated prior to the start of each presentation.

**Faculty Disclosures:**

**Taymeyah Al-Toubah, MPH**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Erica Alexander, M.D.**

- Disclosure of relevant financial relationships:
  - Boston Scientific: Medical Advisory Board
- Unapproved drug or product uses
  - Radioembolization of neuroendocrine tumors.

**Timothy Asmis, MD**

- Disclosure of relevant financial relationships:
  - Consultant: Astra Zeneca, BMS, Eisai, Ipsen, Medison, Merck, Novartis AAA, Roche, Taiho
- No discussion of unapproved drug or product uses.

**Emily Bergsland, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Castigliano M. Bhamidipati, DO, PhD, MSc, FACS, FACC**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Aman Chauhan, MD**

- Disclosure of relevant financial relationships:
  - Research Support: BMS, Clovis, Lexicon, TerSera, EMD Serono, Nanopharmaceutics, ECS Progastrin, Seneca Therapeutics
  - Advisory Board: Novartis/AAA, Seneca Therapeutics, Lexicon, TerSera, Ipsen, ECS Progastrin, Crinetics, Curium
- No discussion of unapproved drug or product uses.

**Dr. Callisia N. Clarke, MD, MS, FACS, FSSO**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Daniel DePietro, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Mr. Simon Desmarais, CNETS Board member and Patient**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Efrat Dotan, MD**

- Disclosure of relevant financial relationships:
  - Amgen, Incyte, Taiho: Advisory Board: Ended in the prior 24 months
  - Gilead, Ipsen, Kinate, Leap Therapeutics, Lilly, Lutris, NGM Biopharmaceuticals, Relay, Zyme works: Research grants paid to institution
  - Olympus: Advisory Board
  - Pfizer: Advisor: Ended in the prior 24 months
- No discussion of unapproved drug or product uses.

**Suzann Duan, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses:
  - The abstract and presentation content will include data on the application of the FDA-approved Smoothened/Hedgehog inhibitor, Vismodegib. Vismodegib has been approved for use in basal cell carcinoma, however it has not yet been investigated thoroughly in other solid tumor types including NETs. The current study includes content in which Vismodegib is applied to NET-derived organoids, that is, solely in EX VIVO preclinical models.

**Dr. Jennifer R Eads, MD**

- Disclosure of relevant financial relationships:
  - Amgen, Arcus, Gilead, Hutchmed: Institutional Research
  - Astra Zeneca, Genetech, Hutchmed: Institutional Research: Ended in prior 24 months
  - Merck: Advisory board; Institutional Research
  - Oncolys, Seagen: Institutional Research
- No discussion of unapproved drug or product uses.

**Po H. Ear, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Douglas B. Evans, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Gabriel Fine, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Valentina Gambardella, M.D. Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses: **BI 764532**

**Alexandra Gangi, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Mr. Hector Gonzalez-Cantu, M.Sc.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Rachel Anne Goodwin, MSc, MD, FRCPC**

- Disclosure of relevant financial relationships:
  - AAA, Novartis, Merck, Taiho, AstraZeneca, Amgen, BMS, Viatrix: Advisory and Consultant Board
  - Ipsen, Pfizer: Received Independent Education Grant, Advisory and Consultant board Speaker Engagements
- No discussion of unapproved drug or product uses.

**Dr. Udhayvir Singh Grewal, M.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Thorvardur R Halfdanarson, M.D.**

- Disclosure of relevant financial relationships:
  - ITM Oncologics GmbH: Scientific Advisor for ITM
- Unapproved drug or product uses:
  - 177Lu-edotreotide for well-differentiated aggressive grade 2/3 gastro-entero-pancreatic neuroendocrine tumors

**Dr Julie H Hallet, MD MSc FRCSC FSSO**

- Disclosure of relevant financial relationships:
  - Bristol Myers Squibb, Medtronic, Novartis: Speaking honoraria: Ended in the prior 24 months
  - Ipsen: Speaking honoraria
- No discussion of unapproved drug or product uses.

**Ms. Jackie Herman**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. James R. Howe, V, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Cezar A. Iliescu, MD, FACC, FSCAI**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Smita Jha, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Camilo Jimenez, MD**

- Disclosure of relevant financial relationships:
  - Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, U.S.A. (MSD), Exelixis, Pfizer, Lantheus Pharmaceuticals, Progenics Pharmaceuticals: Research support
  - MSD, Pfizer, Lantheus Pharmaceuticals, HRA Pharma: Consultant
- Unapproved drug or product uses:
  - This trial in progress is evaluating the efficacy and safety of belzutifan in patients with advanced pheochromocytoma/paraganglioma or pancreatic neuroendocrine tumors.

**Dr. Paola Jimenez Vasquez, M.D**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Nancy Joseph, M.D/Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Hagen F. Kennecke, MD, MHA, FRCP**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses:
  - Cabozantinib in combination with Lu-177 DOTATATE

**Dr. Xavier M Keutgen, MD**

- Disclosure of relevant financial relationships:
  - TherSera Pharmaceuticals: Consulting
- No discussion of unapproved drug or product uses.

**Nikhil I Khushalani, MD**

- Disclosure of relevant financial relationships:
  - Amarin, Asensus Surgical, Bellicum Pharmaceuticals: Common Stock
  - AstraZeneca: Data Safety Monitoring Committee
  - Bristol Myers-Squibb, Regeneron, Replimmune: Advisory Board, Study Steering Committee, Research support (to institution)
  - Castle Biosciences, Instil Bio, Iovance Biotherapeutics: Advisory Board
  - Celgene, GlaxoSmithKline, Modulation Therapeutics, Huya Bioscience International: Research Support (to institution)
  - Incyte: Data Safety Monitoring Committee
  - Merck, Novartis: Advisory Board, Research support (to institution)
  - Nektar: Advisory Board, Study Steering Committee
- Unapproved drug or product uses:
  - Nivolumab, Ipilimumab (Merkel Cell Carcinoma)

**Angela Kosec, NP**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Prof. Dr. Marnix Lam, MD, Ph.D.**

- Disclosure of relevant financial relationships:
  - Boston Scientific, Terumo: Research support / consultant
  - Novartis: Research support: Ended in prior 24 months
- No discussion of unapproved drug or product uses.

**Dr Frank I. Lin, M.D.**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses:
  - Off label use of Lutathera

**Dr. Paul Norman Lindenfeld, M.D.**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses:
  - I intend to discuss some existing drugs that are already FDA approved for other conditions, but I suspect could be very effective in managing refractory diarrhea in advanced NET based upon their pharmacology. I am not recommending these drugs as current standard therapy, but I will hopefully spur interest in these drugs amongst the NET research community so that they can be appropriately studied in a NET population. I will be mentioning: Crofelemer, Glycopyrrolate and other anti-cholinergic drugs that do not cross the blood-brain barrier, Oral Cromolyn and I will also discuss drugs that modulate post synaptic serotonin receptors 5-HT3 and 5-HT4.

**Dr Jonathan M Loree, MD, MSc.**

- Disclosure of relevant financial relationships:
  - Amgen, Ipsen, Novartis: Consulting fees and Research funding
  - AstraZeneca, Foundation Medicine, Personalis Inc.: Research Funding
  - Pfizer, Taiho Pharma, Takeda: Consulting fees
  - SAGA Diagnostics: Consulting fees and Research funding
- No discussion of unapproved drug or product uses.

**Mr. Josh Mailman, MBA**

- Disclosure of relevant financial relationships:
  - Camurus AB: Consultancy/ Advisory Board, Study steering committee
  - Ipsen: Consultancy/ Advisory Board
  - ITM Isotopen Technologien München AG: Consultancy/ Advisory Board
  - Novartis: Consultancy/ Advisory Board
- No discussion of unapproved drug or product uses.

**Dr Mary A. Maluccio, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Ilaria Marinoni, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Belinda H. McCully, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Iacovos Michael, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Lois Mulligan, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Netta Maria Mäkinen, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Eric K Nakakura, MD, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Carolyn Nessim, MD, MSc, FRCSC, FACS**

- Disclosure of relevant financial relationships:
  - Astra Zeneca, Novartis, EMD Sorono: Speakership: Ended in prior 24 months
  - Boehringer: Ad Board: Ended in prior 24 months
  - Merck: Speakership and Ad boards: Ended in prior 24 months
  - Sanofi: Ad Board: Ended in prior 24 months
- No discussion of unapproved drug or product uses.

**Dr. Cédric Nesti, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Michael O'Rorke, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Chris O'Callaghan, DVM, MSc, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Stefano Partelli, MD**

- No relevant financial interests with ineligible entities to disclose.
- Unapproved drug or product uses:
  - 177Lu-DOTATATE for neoadjuvant purpose

**Rodney F Pommier, MD, FACS**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. J. Bart Rose, MD, MAS, FACS**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Prof. Girish M Shah, Ph.D.**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Heloisa Prado Soares, MD, Ph.D.**

- Disclosure of relevant financial relationships:
  - Astra Zeneca, Ipsen, Novartis: Advisory board honorarium
  - ITM: Speaker at symposium
- No discussion of unapproved drug or product uses.

**Katelyn Sommerer, PharmD, MS, BCOP**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Sahithi Savithri Sonti, M.B.B.S**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. Michael C Soulen, MD FSIR FCIRSE**

- Disclosure of relevant financial relationships:
  - AstraZeneca, Genentech, Terumo, Varian: Ad board: Ended in prior 24 months
  - Guerbet LLC, Pfizer, Sirtex: Research grant to institution
- Unapproved drug or product uses:
  - Y90 microspheres for NET liver metastases

**Gabriela Spilberg, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Jonathan Strosberg, MD**

- Disclosure of relevant financial relationships:
  - Ipsen: Speaker's Bureau
  - Novartis: Consultant
- No discussion of unapproved drug or product uses.

**Dr. Heather C Stuart, BSc MSc, MD, FRCSC, FACS**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Nikolaos Trikalinos, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr Radhika Yelamanchili, MD**

- Disclosure of relevant financial relationships:
  - AAA, BMS: Received honorarium
  - Advanz Pharma, Ipsen: Advisory Committee member
  - Eisai, Merck, Pfizer: speaker
- No discussion of unapproved drug or product uses.



**Dr. Mehran Yusuf, MD**

- No relevant financial interests with ineligible entities to disclose.
- No discussion of unapproved drug or product uses.

**Dr. David Bing Zhen, MD**

- Disclosure of relevant financial relationships:
  - AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Legend Biotech, Merck: Roche, Genentech, Seagen, TME Pharma: Research Funding
  - Cornerstone Pharmaceuticals, Ipsen: Consulting/Advisory Board, Research Funding
  - Jazz Pharmaceuticals, Zymeworks: Independent Data Monitoring Committee
  - QED Therapeutics, Inc: Consulting and Advisory Board
- No discussion of unapproved drug or product uses.

**Mitigation of Relevant Financial Relationships**

AffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). Relevant financial interests when present was mitigated through peer review of content by a non-conflicted reviewer prior to the commencement of the activity.

**Activity Accreditation for Health Professions****Physicians**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 18.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Physicians for ABIM Maintenance of Certification**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 Medical Knowledge-only MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### Physicians for ABS Continuous Certification



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn 11.5 credits toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility submit learner completion information to ACCME for the purpose of granting ABS credit.

### Use of Learner Data

Learner data will be shared with ACCME and the applicable certifying board. For ABIM MOC Credit and/or ABS CC credit to be reported, evaluations and post-test must be completed prior to the deadline (October 30, 2023).

### Physician Assistants



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 18.25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

### Nurse Practitioners



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of

AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 18.25 *AMA PRA Category 1 Credits™*. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

## Nurses



Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 18.25 hours of continuing nursing education credit.

## Pharmacists



AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).

This knowledge-based CPE activity will provide up to 18.25 contact hours for participants. Cost to participate in these CE activities is included in the registration. Participant CE records will be electronically communicated to CPE Monitor. UANs are associated with each session.

## Technologists and Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

## Commercial Support

No commercial support was received for this activity.

## Participation Costs

The cost to participate in this CE activity is included in the registration for the conference.

## CME Inquiries

For all CME policy-related inquiries, please contact us at [ce@affinityced.com](mailto:ce@affinityced.com). Send customer support requests to [cgs\\_support+nanets@affinityced.com](mailto:cds_support+nanets@affinityced.com).

## How to Claim CE Credit

Registration for the conference does not establish an account in the CE Center or automatically provide continuing education credit. You must sign into the CE Center site and evaluate the content of the activity to earn CE credit.

1. Please go to [nanets.cds.affinityced.com](https://nanets.cds.affinityced.com).
2. Select **NANETS 2023 Multidisciplinary NET Medical Symposium**
3. On the login page, enter your e-mail address and desired password. Select “I Forgot My Password” if you need to reset the password you set up.
4. Complete, verify, or correct your demographic information and select your profession. You may select multiple professions. Click “Continue” to proceed.
5. Complete session evaluations and post-tests where applicable for ABIM or ABS certification; then click “Submit My Evaluation” and proceed.
6. Participants claiming pharmacist CE credits will need to supply their date of birth and NABP e-Profile ID. Pharmacy CE records will be electronically communicated to CPE Monitor.
7. When you have completed the session evaluations (and any post-tests for ABIM or ABS credit), you can download your CE certificate. Your CE certificate will also be stored here for later retrieval.
8. The website will remain open to claim credit until October 30, 2023.
9. You can return to the site at any time to download your certificate.
10. **If you want to claim MOC credit for ABIM or ABS, please e-mail your name, e-mail address, and phone number to [support@affinityced.com](mailto:support@affinityced.com). In approximately one week, we will provide access for you to claim MOC credit.**

Please send any customer service requests to [cds\\_support+nanets@affinityced.com](mailto:cds_support+nanets@affinityced.com).